MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。

U0126-EtOH

CAS No. : 1173097-76-1

MCE 國際站：U0126-EtOH

產(chǎn)品活性：U0126-EtOH 是一種有效，非 ATP 競(jìng)爭(zhēng)性的，選擇性的 MEK1 和 MEK2 抑制劑，IC₅₀ 分別為 72 nM 和 58 nM。U0126-EtOH 是一種自噬 (autophagy) 和線粒體自噬 (mitophagy) 抑制劑。

研究領(lǐng)域：MAPK/ERK Pathway  |  Autophagy  |  Anti-infection

作用靶點(diǎn)：MEK  |  Autophagy  |  Mitophagy  |  Influenza Virus

In Vitro: Treatment with U0126-EtOH (U0126) efficiently reduces progeny virus titers of all tested strains in A549 cells. While nM concentrations of U0126-EtOH are efficient to reduce H1N1v and H5N1 (MB1), μM concentrations of U0126-EtOH are required to reduce the virus titer of H5N1 (GSB) and H7N7. The EC₅₀ values for U0126-EtOH against H1N1v are 1.2±0.4 μM in A549 cells and 74.7±1.0 μM in MDCKII cells.
Rat hepatocarcinoma cells (FAO) stimulated by fetal calf serum (FCS) exhibits a significant proportion in S phase (32.62%) whereas U0126-EtOH (U0126) strongly decreases the proportion of cells in S phase (9.92%) and increases the proportion of cells in G₀-G₁ phase and to a lesser extent in G₂/M.

In Vivo: Mice are treated daily with U0126-EtOH (U0126; i.p., 10.5 mg/kg). In control experiment, tumor sizes are constant or slightly increase all over the kinetic. At the opposite, in all U0126-EtOH experiments, engraftment and early tumor growth are significantly decreased. Furthermore, a 60-70% reduction in the volume of tumors treated with U0126-EtOH is obtained 9 days after injection and thereafter.
Rats are subjected to 120 minutes transient middle cerebral artery occlusion (tMCAO) and thereafter treated with the U0126-EtOH (U0126; i.p., 30 mg/kg) at 0 and 24 hours of reperfusion. After treatment with U0126-EtOH, the vasoconstriction to S6c is markedly reduced.

相關(guān)產(chǎn)品：Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Immunology/Inflammation Compound Library  |  Kinase Inhibitor Library  |  MAPK Compound Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Reprogramming Compound Library  |  Oxygen Sensing Compound Library  |  Ferroptosis Compound Library  |  Glutamine Metabolism Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Obesity Compound Library  |  Angiogenesis-Related Compound Library  |  Mitochondria-Targeted Compound Library  |  Anti-Liver Cancer Compound Library   |  Anti-Colorectal Cancer Compound Library   |  Pain-Related Compound Library  |  Highly Selective Inhibitors Library  |  Cell Death Library  |  Serine/Threonine Kinase Inhibitor Library  |  Ganoderic acid TR  |  Avutometinib  |  Curcumin  |  Cap-dependent endonuclease-IN-23  |  Ermanin  |  Carbamazepine-d₂  |  Hypericin  |  Cobimetinib racemate  |  (E/Z)-Zeatin  |  Trifluoperazine dihydrochloride  |  Salicylic acid-¹³C₆  |  1-Deoxymannojirimycin hydrochloride  |  HA-IN-1  |  Rimantadine-d₄ hydrochloride  |  Trametinib (DMSO solvate)  |  Olaparib-d₈  |  FR198248  |  Aspirin-d₄  |  Amantadine-d₆  |  CEF1, Influenza Matrix Protein M1 (58-66)  |  Drechslerine A  |  Ketotifen fumarate  |  Herquline A  |  Coptisine chloride  |  Ginsenoside Rb2  |  PD184161  |  Resveratrol  |  Salicylic acid-d₆  |  Sulfosuccinimidyl oleate sodium  |  Sophocarpine monohydrate

熱門產(chǎn)品線：重組蛋白  |  化合物庫  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標(biāo)記物  |  寡核苷酸  |  抗體  |  點(diǎn)擊化學(xué)

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry